June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Efficacy of rebamipide for laser in situ keratomileusis-associated dry eye
Author Affiliations & Notes
  • Yosai Mori
    Miyata Eye Hospital, Miyakonojo, Japan
  • Ryohei Nejima
    Miyata Eye Hospital, Miyakonojo, Japan
  • Ayami Masuda
    Miyata Eye Hospital, Miyakonojo, Japan
  • Yoko Maruyama
    Miyata Eye Hospital, Miyakonojo, Japan
  • Keiichiro Minami
    Miyata Eye Hospital, Miyakonojo, Japan
  • Kazunori Miyata
    Miyata Eye Hospital, Miyakonojo, Japan
  • Footnotes
    Commercial Relationships Yosai Mori, None; Ryohei Nejima, None; Ayami Masuda, None; Yoko Maruyama, None; Keiichiro Minami, None; Kazunori Miyata, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 945. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yosai Mori, Ryohei Nejima, Ayami Masuda, Yoko Maruyama, Keiichiro Minami, Kazunori Miyata; Efficacy of rebamipide for laser in situ keratomileusis-associated dry eye. Invest. Ophthalmol. Vis. Sci. 2013;54(15):945.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Dry eye syndrome is a major complication after laser in situ keratomileusis (LASIK), and is occasionally hard to improve with an artificial tear or hyaluronic acid treatment. Rebamipide is a quinolinone derivative stimulating mucin secretion as well as increasing goblet cells on the conjunctiva, resulting in improvement of ocular surface disorders. Aim of the study is to evaluate the efficacy of rebamipide for dry eye after LASIK.

Methods: This prospective study comprised 32 eyes of 16 patients who had LASIK-associated dry eye and had been treated with the artificial tear or hyaluronic acid eye drop. Rebamipide 2% eyedrop (Mucosta, Ohtsuka Pharmaceutical) was additionally instilled 4 times a day for 4 weeks. Tear secretin was examined with the Schirmer test with anesthesia before and at 4 weeks after the rebamipide treatment. Tear breakup time (BUT), fluorescein stain, and lissamine green stain were examined before and at 1 and 4 weeks. Fluorescein staining on the cornea was evaluated by the summation of area and density scores (none:0 to severe:3). Lissamine green staining in the conjunctiva was scored in none:0 to full:18. Questionnaire of 14 symptoms according to Ocular Surface Disease Index was performed before and at 4 weeks. Change in the examinations after the additional treatment was evaluated with the Friedman's test following Scheffe ad-hoc comparison. Symptoms were compared with the Wilcoxon signed-ranks test.

Results: Mean tear secretin did not change beween before rebamipide treatment (8.8 mm) and after 4 weeks (8.2 mm). BUT significantly increased from before (3.4 sec.) to 1 week (4.8 sec., P<0.001), and continued up to 4 weeks (5.0 sec.). Fluorescein and lissamine green staining scores were also improved from 1 week after the rebamipide treatment (P<0.001). There were significant improvement in 9 symptoms (fatigue, dryness, grittiness, heavy eyelids, pain, discomfort, blurred vision, light sensitivity, dry place).

Conclusions: Addition of rebamipide 2% improved ocular surface disorder and dry eye symptoms. It was demonstrated that mucin secretion in the tear film due to the rebamipide effectively improved LASIK-associated dry eye.

Keywords: 486 cornea: tears/tear film/dry eye • 485 cornea: surface mucins • 680 refractive surgery: complications  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.